NCT03810183View on ClinicalTrials.gov

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

QAW039

QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care

DRUG

Placebo

Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care

Trial Locations (4)

20354

Novartis Investigative Site, Hamburg

30625

Novartis Investigative Site, Hanover

60596

Novartis Investigative Site, Frankfurt

BD9 6RJ

Novartis Investigative Site, Bradford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY